Crucell Holland
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Crucell Holland sits in the top decile of US sponsors by registered trial count (#1,331 of 15,751 sponsors by registered trial count).
Crucell Holland: 10 sponsored US clinical trials, none currently recruiting.
Crucell Holland sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 10 completed. 1 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 1 trials.
Top-decile sponsor footprint
Crucell Holland ranks in the top decile of sponsors by registered trial count (#1,331 of 15,751 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Indexed trials (enrollment closed)
10 total, page 1 of 1
A Study to Evaluate the Immunogenicity, Safety and Tolerability of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants
NCT02543268
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad26.RSV.FA2 Followed by Ad35.RSV.FA2 in Healthy Adult Volunteers
NCT02561871
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Participants
NCT02440035
Safety, Tolerability and Immunogenicity Study of 2 Dose Levels of Trimeric Glycoprotein140 (gp140) in Healthy Adult Volunteers
NCT02304185
A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults
NCT02218125
Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus
NCT01406418
Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses
NCT01756950
Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza Patients
NCT01839760
A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model
NCT01397227
A Randomized Phase II Trial to Compare the Safety and Neutralizing Activity of CL184 in Combination With Rabies Vaccine vs. HRIG or Placebo in Combination With Rabies Vaccine in Healthy Adult Subjects
NCT00656097
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 7 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Therapeutic Areas
How the Crucell Holland early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 10 completed (100%).
Phase mix: 1 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Healthy (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial from this sponsor, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.